SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

Inclusion Criteria: Histologically or cytologically confirmed systemic anaplastic large cell lymphoma (ALCL) Tissue available for the determination of anaplastic large cell kinase (ALK) status [t(2;5), ALK-NPM translocation] prior to study entry Prior steroids or topical treatments are allowed. Patients who are on chronic steroid therapy may receive concomitant steroids provided they have been on a stable dosage for at least 3 months prior to enrollment Measurable disease, defined as >= 1 lesion that can be accurately measured in >= 1 dimension (longest diameter to be recorded) as >= 20 mm by conventional techniques or as >= 10 mm by spiral CT scan The Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 OR Karnofsky PS 70-100% White Blood Count (WBC) >= 3,000/mm³ Absolute neutrophil count >= 1,500/mm³ Platelet count >= 100,000/mm³ (unless due to lymphoma [i.e., splenomegaly and/or bone marrow involvement]) Bilirubin =< 1.5 times upper limit of normal (ULN) AST or ALT =< 2.5 times ULN Creatinine =< 1.5 times ULN (unless due to lymphoma) OR creatinine clearance >=60 mL/min Left ventricular ejection fraction (LVEF) >= 50% Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after completion of study treatment Exclusion Criteria: No rapidly progressing disease or bulky disease, defined as a mass of > 7 cm in largest diameter No primary cutaneous ALCL No known brain metastases No concurrent combination antiretroviral therapy for HIV-positive patients No history of allergic reactions attributed to compounds of similar chemical or biological composition to monoclonal antibody SGN-30 No uncontrolled intercurrent illness, including, but not limited to, any of the following: Ongoing or active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness or social situations that would preclude study compliance No prior or other concurrent malignancy with < 90% probability of survival at 5 years No other concurrent anticancer agents or therapies No prior chemotherapy for ALCL No other concurrent investigational agents